Educational Notice
This article is written for researchers, formulators, clinicians, and informed consumers seeking to understand the published evidence on palmitoyl hexapeptide-12. It is not medical advice, a treatment recommendation, or an endorsement of any product. Palmitoyl hexapeptide-12 is a cosmetic ingredient — not a pharmaceutical drug — and is not evaluated by the FDA for safety or efficacy. Consult a qualified dermatologist or healthcare professional before making decisions about your skin health.
A Comprehensive Evidence Review for Researchers, Formulators, and Informed Consumers
Palmitoyl hexapeptide-12 is the last compound in Peptidings’ Cluster G review, and in terms of published evidence it is the most thinly supported of the twelve. It appears in product INCI lists — sometimes prominently featured in marketing — with proposed muscle-relaxing effects framed in the familiar anti-wrinkle language of the NMJ-targeting peptide category. The mechanism sounds plausible in summary: a palmitoylated hexapeptide designed to inhibit acetylcholine release and reduce facial muscle contraction. The evidence is almost entirely absent. Not weak — absent. No published independent clinical trials, no published mechanistic studies in PubMed-indexed journals, and manufacturer documentation that is less accessible than even Snap-8 or leuphasyl, which at least have technical dossiers with described study parameters.
This article will be shorter than most Cluster G articles because the evidence is thinner. That is not a failing of the format — it is an accurate reflection of what exists. A compound with minimal published evidence does not warrant the same depth of evidence analysis as one with clinical trials, however flawed, to examine. What this article can do is explain the proposed mechanism, place the compound in the context of its NMJ-targeting peers, be explicit about what distinguishes its evidence position from the other preclinical compounds in the cluster, and assess each delivery route with the same framework applied throughout this cluster.
Quick Facts
INCI Name
Palmitoyl Hexapeptide-12
Mechanism Class
Proposed neurotransmitter inhibitor — acetylcholine release reduction at NMJ via uncharacterized mechanism
Evidence Tier
Preclinical Only
Regulatory Status
Cosmetic ingredient — not a drug. No FDA approval or evaluation required.
WADA Status
Not prohibited
Typical Topical Concentration
Supplier recommendations: 1–5%; no published clinical study anchor
Molecular Weight
~1,025 Da — well above the 500 Da passive penetration threshold
Tradename
Bont-L Peptide® (Infinitec Activos / various suppliers)
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
What Is Palmitoyl Hexapeptide-12?
Palmitoyl hexapeptide-12 (INCI: palmitoyl hexapeptide-12; tradename Bont-L Peptide® in some supplier contexts) is a palmitoylated synthetic hexapeptide proposed to reduce facial muscle contraction by inhibiting acetylcholine release at the neuromuscular junction. Its sequence is Pal-VGVAPG (palmitoyl-Val-Gly-Val-Ala-Pro-Gly) — an elastin-derived hexapeptide sequence with a palmitoyl chain for lipophilic stratum corneum penetration.
The VGVAPG sequence is notable independent of the cosmetic peptide context. It is a repeating hexapeptide from the hydrophobic domain of elastin — the protein responsible for skin’s elastic recoil — and has been studied in its own right as a biological signaling sequence. In the extracellular matrix biology literature, VGVAPG fragments released during elastin degradation act as chemoattractants and activate inflammatory and repair responses via the elastin binding protein (EBP) / galectins receptor complex. This is not the mechanism relevant to palmitoyl hexapeptide-12’s proposed cosmetic use — the anti-wrinkle claim is based on acetylcholine release inhibition, a mechanistically distinct action.
At approximately 1,025 Da, palmitoyl hexapeptide-12 has one of the highest molecular weights of any compound in Cluster G — comparable to Snap-8 (1,075 Da) and well above the 500 Da passive penetration threshold. The penetration challenge is substantial for a compound proposed to reach the NMJ depth.
Origins and Development
Palmitoyl hexapeptide-12 was developed by Infinitec Activos, a Spanish cosmetic ingredient company, as part of their Bont-L peptide line — a family of peptides marketed as alternatives to botulinum toxin for cosmetic use. The VGVAPG sequence was selected for its elastin origin and proposed interactions with receptor systems at the NMJ. Unlike Lipotec’s NMJ-targeting peptides (argireline, leuphasyl, Snap-8), which have explicit mechanistic characterization in published or manufacturer technical documentation with described studies, palmitoyl hexapeptide-12’s evidence documentation is less transparent in public-facing form.
The ingredient entered the market and began appearing in product formulations in the 2010s, positioned alongside argireline and Snap-8 in multi-peptide NMJ-targeting formulations. Its market adoption preceded any meaningful published clinical evidence, which is consistent with the general pattern in the cosmetic ingredient industry but is particularly pronounced for this compound.
Proposed Mechanism of Action
The proposed mechanism for palmitoyl hexapeptide-12 is inhibition of acetylcholine release at the neuromuscular junction — the same functional endpoint targeted by argireline (SNARE inhibition), Snap-8 (extended SNARE inhibition), leuphasyl (enkephalin pathway), and Syn-Ake (postsynaptic nAChR blockade). The molecular target through which VGVAPG is proposed to reduce acetylcholine release is less well-characterized than for these other compounds.
Plain English
Palmitoyl hexapeptide-12 is designed to mimic a fragment of a natural immune signaling protein (immunoglobulin) to reduce skin inflammation. The palmitoyl (fatty acid) tail helps it penetrate the skin’s outer barrier, while the peptide portion interacts with immune cells to calm inflammatory responses associated with redness and sensitivity.
Supplier documentation suggests the mechanism involves interaction with the muscular nicotinic acetylcholine receptor complex or with presynaptic vesicle release machinery, but the specific molecular target and binding characterization available in published literature is limited. The VGVAPG sequence’s known receptor interaction is through the elastin binding protein (EBP) / galectin-3 complex — a receptor system involved in elastin and galactoside signaling rather than NMJ neurotransmitter release. Whether the palmitoylated cosmetic peptide engages the NMJ through the EBP pathway, through a distinct mechanism, or through a mechanism that remains unpublished is not clear from available public information.
Plain English
The other NMJ-targeting peptides in this cluster have specific, named molecular targets that have been characterized in published or manufacturer studies: argireline targets SNARE proteins, leuphasyl targets opioid receptors, Syn-Ake targets nicotinic acetylcholine receptors. Palmitoyl hexapeptide-12’s NMJ mechanism is described in general terms in supplier documentation without the same level of molecular target specificity available in the public record. The claim is plausible as a category; the specific mechanism is not well-documented.
Palmitoyl Hexapeptide-12 Among the NMJ-Targeting Peptides
All five NMJ-targeting peptides in Cluster G — argireline, Snap-8, leuphasyl, Syn-Ake, and palmitoyl hexapeptide-12 — target the same functional endpoint: reduced acetylcholine-mediated facial muscle contraction. Placed in the evidence hierarchy alongside its peers, palmitoyl hexapeptide-12 occupies the weakest position.
| Compound | Molecular Target | MW | Evidence Level |
|---|---|---|---|
| Argireline | SNARE complex (presynaptic) — well-characterized | 889 Da | Pilot / published peer-reviewed studies |
| Syn-Ake | Postsynaptic nAChR — well-characterized | 582 Da | Pilot / manufacturer technical documentation |
| Leuphasyl | Delta/mu opioid receptors — characterized in combination study | 714 Da | Preclinical / combination study only |
| Snap-8 | Extended SNARE complex — in vitro characterized; unpublished clinical documentation | 1,075 Da | Preclinical / manufacturer documentation |
| Palmitoyl Hexapeptide-12 | NMJ mechanism — not specifically characterized in available public literature | 1,025 Da | Preclinical / minimal published data |
The Evidence: What Exists and What Does Not
A systematic search of PubMed for “palmitoyl hexapeptide-12,” “palmitoyl hexapeptide 12,” “VGVAPG cosmetic,” and related terms does not return published peer-reviewed clinical trials or mechanistic studies characterizing the NMJ-inhibiting activity of this specific compound. The VGVAPG sequence itself has independent published research — primarily in the context of elastin-derived peptide biology, chemotaxis, and matrix biology — but this research does not characterize NMJ inhibition or anti-wrinkle activity.
Supplier and manufacturer technical documentation for palmitoyl hexapeptide-12 exists in the form of ingredient specification sheets and product data sheets describing anti-wrinkle claims, but the underlying study methodology — sample sizes, controlled conditions, measurement endpoints — is not publicly available in the detail that characterizes even the weakest entries in the Lipotec or Sederma technical dossiers. Review articles on cosmetic peptides (Gorouhi and Maibach 2009; Schagen 2017) do not include palmitoyl hexapeptide-12 by name.
Evidence note: Palmitoyl hexapeptide-12 has a weaker published evidence position than any other compound in Cluster G, including the other preclinical-tier compounds. Snap-8 has unpublished manufacturer clinical documentation with at least described study parameters. Leuphasyl has in vitro opioid receptor binding data and a described combination study. Tripeptide-29 has independent academic literature on the Gly-Pro-Hyp sequence. Palmitoyl hexapeptide-12 has supplier product sheets. This is not the same thing as evidence.
Common Claims versus Current Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “Inhibits muscle contraction / reduces expression lines” | The proposed mechanism is NMJ acetylcholine inhibition. The specific molecular target is not characterized in available public literature. No published clinical trial exists. Supplier product sheets describe anti-wrinkle effects but do not constitute published evidence. | Mechanism proposed but not characterized; no clinical evidence |
| “Works synergistically with argireline” | If the mechanism is genuinely NMJ-targeted through a different molecular pathway than SNARE inhibition, a combination with argireline could theoretically produce additive effects. Without molecular target characterization, whether it actually acts through an independent pathway cannot be confirmed. No combination study exists. | Synergy logic unverifiable without target characterization |
| “Comparable to other NMJ-targeting peptides” | No head-to-head comparison exists. Other NMJ peptides have at least characterized molecular targets and some form of mechanistic study. Palmitoyl hexapeptide-12 sits at the weakest evidence position in this category. | No comparative evidence; weakest evidence in the NMJ peptide group |
| “Safe and effective for SC injection” | No published safety or efficacy data for any route, including SC injection. Same pharmacological arguments against SC apply as for other NMJ-targeting palmitoylated peptides — systemic distribution without NMJ specificity. | No evidence for any route; SC rationale particularly weak |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
The Human Evidence Landscape
There is no human clinical evidence for palmitoyl hexapeptide-12 in published literature. There is no published mechanistic characterization of its NMJ activity in a peer-reviewed journal. The only supporting material in the public domain consists of supplier product data sheets and marketing materials. This is the weakest evidence position among all twelve Cluster G compounds, and among the weakest in the entire Peptidings compound library.
The honest question this raises is: why is this compound included in skincare formulations at all? The answer is commercial rather than evidential. Products that contain multiple NMJ-targeting peptides — argireline, Snap-8, Syn-Ake, leuphasyl, and palmitoyl hexapeptide-12 together — can legitimately claim to contain a comprehensive multi-mechanism NMJ inhibitor stack, appealing to sophisticated consumers who research peptide combinations. The inclusion of palmitoyl hexapeptide-12 adds another INCI name to the list at relatively low cost. Whether it adds any clinical benefit cannot be confirmed or denied from available evidence.
Safety, Risks, and Limitations
Topical Safety
Palmitoyl hexapeptide-12 has been in commercial cosmetic use without generating significant reported adverse events. The palmitoylated peptide category as a whole has a favorable safety record. Contact sensitization is not a prominently reported concern. The compound is assumed safe for topical cosmetic use based on commercial experience and structural analogy to other palmitoylated cosmetic peptides. The absence of specific published safety studies is noted but is not unique to this compound in the cosmetic ingredient industry.
Microneedling Safety Considerations
Microneedling with palmitoyl hexapeptide-12 is practiced in some community contexts, typically as part of a multi-peptide NMJ stack. The same penetration rationale applies as for argireline and Snap-8 — bypass of the stratum corneum to improve delivery toward NMJ depth. At ~1,025 Da, palmitoyl hexapeptide-12 faces a substantial penetration barrier similar to Snap-8 (1,075 Da), and microneedling provides meaningful relative benefit. No specific trial data exists. Standard sterility caveats apply.
Subcutaneous Injection Safety
No published safety data. Palmitoylated peptide chemistry is designed for stratum corneum lipid penetration, not systemic delivery — the same argument that applies to palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 against SC injection applies here. The proposed NMJ-targeting mechanism relies on local delivery near facial motor nerve terminals; SC injection distributes systemically without facial specificity. Non-sterile cosmetic-grade source material. No defensible justification.
Legal and Regulatory Status
Palmitoyl hexapeptide-12 is a cosmetic ingredient regulated under standard cosmetic frameworks in the US and EU. No FDA pre-market approval is required. In the EU, Regulation EC 1223/2009 applies. The ingredient appears in INCI lists as “palmitoyl hexapeptide-12” and is available from multiple cosmetic ingredient suppliers. The tradename Bont-L Peptide® is associated with Infinitec Activos; generic palmitoyl hexapeptide-12 from other manufacturers is chemically equivalent at the same concentration. WADA status: not prohibited.
Formulation Considerations
Concentration: No published clinical study provides a concentration anchor. Supplier recommendations typically suggest 1–5% in finished formulations. Without a studied concentration range, any specific formulation percentage is arbitrary relative to evidence-based practice.
Stability: Palmitoyl hexapeptide-12 is reported to be stable across a pH range of 4–8 and compatible with standard cosmetic actives, consistent with other palmitoylated peptides in this molecular weight range.
Formulation rationale: The honest formulation case for palmitoyl hexapeptide-12 is thin. If the goal is NMJ inhibition, argireline has better-characterized mechanism and published clinical data. Leuphasyl adds a genuinely independent mechanism through the enkephalin pathway. Syn-Ake adds postsynaptic complementarity. Snap-8 adds extended SNARE inhibition with at least described manufacturer studies. Palmitoyl hexapeptide-12 adds a sixth NMJ-targeting claim at a cost, with the weakest supporting rationale of the group. Whether it provides any additional clinical benefit in a formulation that already contains argireline, leuphasyl, and Syn-Ake is genuinely unknown and pharmacologically uncertain given that its molecular target is uncharacterized.
Dosing and Delivery: What the Research Shows
Topical Application
No published human clinical study exists. Supplier recommendations suggest 1–5% in finished formulations applied to expression-line areas. At ~1,025 Da, passive penetration through intact stratum corneum is limited — the molecular weight sits in the range where palmitoylation provides meaningful lipid-phase anchoring, which is the delivery strategy this compound employs. Without a clinical study establishing an effective concentration range, the 1–5% recommendation is a supplier convention rather than an evidence-based protocol.
Microneedling / Stamping
Microneedling with palmitoyl hexapeptide-12 is used in the self-experimentation community, typically as part of a multi-NMJ-peptide solution alongside argireline, leuphasyl, and/or Syn-Ake. No published trial data exists. The high molecular weight (~1,025 Da) means microneedling penetration enhancement is proportionally valuable — similar to the argument for Snap-8. Standard sterility caveats apply.
Subcutaneous Injection
No published data. Palmitoylated chemistry is designed for topical lipid-barrier delivery, not systemic distribution. No characterized molecular target. No evidence for any route. No pharmaceutical sterility standard. SC injection has no defensible basis for any cosmetic peptide in this cluster, and least of all for one whose mechanism is not even specifically characterized in the public literature.
Delivery Routes in Self-Experimentation Communities
| Route | Community Use | Evidence | Key Risks |
|---|---|---|---|
| Topical serum/cream | Moderate — appears in commercial multi-NMJ-peptide formulations; used in DIY peptide stacks | Supplier product sheets only — no published clinical studies, no published mechanistic studies | Low — palmitoylated peptide category has favorable safety record; source quality varies |
| Microneedling / stamping | Practiced — included in multi-peptide microneedling solutions; high MW makes penetration enhancement valuable | No published data of any kind for this route or compound | Moderate — sterility of source material; NMJ depth beyond microneedling range |
| SC injection | Rare — uncharacterized mechanism recognized as a concern even among community members who regularly inject other peptides | No published data | Higher — palmitoyl chemistry is topical delivery strategy; uncharacterized NMJ mechanism; non-sterile source material; no evidence for any outcome |
In the self-experimentation community, palmitoyl hexapeptide-12 appears primarily as an ingredient in commercial products rather than as an intentional DIY addition — its inclusion in formulations is more often a product formulator’s decision than a self-experimenter’s deliberate choice. Community members researching peptide stacks tend to prioritize argireline, leuphasyl, and Syn-Ake for their better-characterized mechanisms, with palmitoyl hexapeptide-12 a secondary or passively-encountered addition. The relatively limited community discussion around this specific compound, compared to argireline or Syn-Ake, reflects the thinner evidence base and less developed mechanism story.
Frequently Asked Questions
Q: What is palmitoyl hexapeptide-12 and what does it claim to do?
A: Palmitoyl hexapeptide-12 (INCI: palmitoyl hexapeptide-12, sequence Pal-VGVAPG) is a palmitoylated synthetic hexapeptide derived from the elastin sequence VGVAPG. It is marketed as an NMJ-targeting peptide that inhibits acetylcholine release to reduce facial muscle contraction and soften expression lines — the same functional category as argireline, Syn-Ake, and leuphasyl. The specific molecular target through which it produces this effect is not characterized in available public literature, and no published peer-reviewed clinical trials or mechanistic studies for its NMJ activity exist in PubMed-indexed journals.
Q: What evidence exists for palmitoyl hexapeptide-12?
A: Minimal. No published human clinical trials. No published peer-reviewed mechanistic studies characterizing NMJ inhibition by this specific compound. The VGVAPG sequence has independent published biology as an elastin-derived matrikine and chemoattractant — but this research relates to elastin binding protein (EBP) receptor biology, not NMJ acetylcholine inhibition. The anti-wrinkle evidence consists of supplier product data sheets. This is the weakest evidence position of any compound in Peptidings’ Cluster G review.
Q: How does palmitoyl hexapeptide-12 compare to argireline?
A: Argireline has a well-characterized SNARE complex mechanism published in peer-reviewed journals, small clinical studies published in peer-reviewed journals, and decades of commercial history with documented outcomes. Palmitoyl hexapeptide-12 has a proposed NMJ mechanism with uncharacterized molecular target and no published clinical or mechanistic data. They are in the same functional category (NMJ-targeting anti-wrinkle peptides) but at very different evidence levels. Choosing palmitoyl hexapeptide-12 over argireline as a primary NMJ inhibitor in a formulation cannot be justified by evidence.
Q: Is the VGVAPG sequence biologically active?
A: Yes — but not in the way palmitoyl hexapeptide-12’s anti-wrinkle claims suggest. The VGVAPG sequence is a repeating unit from the hydrophobic domain of elastin and has been characterized as a chemoattractant that signals via the elastin binding protein (EBP) / galectin-3 receptor complex. This biology involves cell migration, matrix remodeling, and inflammatory signaling — not NMJ neurotransmitter inhibition. The VGVAPG biology in published literature does not directly validate the acetylcholine release inhibition claim made for palmitoyl hexapeptide-12.
Q: Can palmitoyl hexapeptide-12 be used with microneedling?
A: It can be, and its high molecular weight (~1,025 Da) means microneedling penetration enhancement is proportionally valuable — similar to Snap-8 at 1,075 Da. No palmitoyl hexapeptide-12-specific microneedling trial exists. Standard sterility concerns apply as for all cosmetic-grade microneedling applications. If including it in a microneedling solution, the same sterility standards for source material apply as for any other ingredient used below the stratum corneum.
Q: Does including palmitoyl hexapeptide-12 improve an argireline + leuphasyl + Syn-Ake formulation?
A: Unknown — and the unknowns are compounded by the fact that the molecular target is uncharacterized. Argireline + leuphasyl + Syn-Ake covers three mechanistically independent and well-characterized NMJ inhibition pathways (SNARE presynaptic, enkephalin presynaptic, nAChR postsynaptic). Whether palmitoyl hexapeptide-12 acts through a fourth independent pathway (in which case it might add value) or through one of the same pathways at lower potency (in which case it adds redundancy) cannot be determined without knowing its specific molecular target. The honest answer is: nobody has published data that answers this question.
Q: Is SC injection of palmitoyl hexapeptide-12 effective?
A: No published evidence exists for SC injection of this compound via any route. The palmitoyl chemistry is designed for topical stratum corneum lipid-phase penetration, not systemic delivery. SC injection distributes the compound throughout the body without facial NMJ specificity — the same argument that applies to all palmitoylated cosmetic peptides. With the additional uncertainty of an uncharacterized NMJ mechanism, SC injection of palmitoyl hexapeptide-12 has even less pharmacological justification than for compounds like argireline, where at least the molecular target at the NMJ is specifically known.
Q: Should I use palmitoyl hexapeptide-12 in my skincare routine?
A: If you are looking for NMJ-targeted anti-wrinkle peptides with actual published evidence behind them, argireline (SNARE inhibitor, published peer-reviewed clinical data), Syn-Ake (nAChR antagonist, manufacturer study with described parameters), and leuphasyl (enkephalin pathway, characterized mechanism, combination study data) are the better-supported choices in this category. Palmitoyl hexapeptide-12 adds a claim without adding characterized mechanism or published evidence. It is not harmful at topical cosmetic concentrations — the category safety record is favorable — but it cannot be described as clinically supported anti-wrinkle ingredient based on currently available published evidence.
PART-B:
Related Compounds: How Palmitoyl Hexapeptide-12 Compares
Palmitoyl hexapeptide-12 is categorized as an NMJ-targeting peptide alongside argireline, Snap-8, leuphasyl, and Syn-Ake — all targeting the same functional endpoint of reduced facial muscle contraction through different proposed mechanisms. It has the weakest evidence position in this group: less mechanistic characterization than any of its peers, no published clinical data, and no PubMed-indexed independent studies. The table below shows all twelve compounds in the Skin & Cosmetic cluster for direct comparison across mechanisms, evidence tiers, and delivery route data.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Skin Target / Mechanism | Typical Concentration | Route | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Argireline (Acetyl Hexapeptide-3) | Synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, SNAP-25 modulator) | SNARE complex disruption / Botox-like wrinkle reduction (proposed) | ~2–4 hours (topical; serum stability uncertain) | Not FDA-approved (cosmetic ingredient, GRAS status for topical use) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Expression wrinkles (periorbital, forehead); muscle contraction inhibition (proposed topical analog to botulinum toxin mechanism) | Typically 3–5% in cosmetic formulations | Topical (creams, serums, cosmetics) | Botox alternative for topical use. Synthetic SNARE inhibitor design. Limited published clinical efficacy vs. marketing claims |
| Matrixyl (Palmitoyl Pentapeptide-4) | Synthetic pentapeptide conjugated to palmitic acid (Pal-GVQPR, collagen-stimulating) | Procollagen upregulation (TGF-β pathway proposed); collagen I/III synthesis | ~1–3 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Dermal collagen remodeling; fine-line reduction; skin firmness (proposed) | Typically 1–3% in cosmetic formulations | Topical (creams, anti-aging serums) | First-generation palmitoyl peptide anti-aging cosmetic. Synthetic TGF-β mimic. Limited independent clinical validation |
| Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Blend) | Synthetic blend of two palmitoyl peptides (Pal-GHK + Pal-GHKGQ, synergistic collagen/elastin remodeling) | Dual collagen + elastin upregulation (proposed; broader TGF-β pathway activation) | ~1–3 hours (topical) | Not FDA-approved (cosmetic ingredient blend) | Not WADA-listed (topical cosmetic peptide blend) | Tier 4 — Preclinical Only | Dermal collagen and elastin remodeling; wrinkle depth and skin texture improvement (proposed) | Typically 1–3% in cosmetic formulations (as synergistic blend) | Topical (creams, serums, moisturizers) | Second-generation peptide blend (Matrixyl + Palmitoyl Tetrapeptide-7). Synergistic formulation strategy. Limited peer-review studies |
| Snap-8 (Acetyl Octapeptide-3) | Synthetic octapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Gly-Gly-NH2, extended Argireline analog) | Extended SNARE modulation / Acetylcholine inhibition (proposed Botox alternative) | ~2–4 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Expression wrinkles (dynamic lines); neuromuscular junction relaxation analog (topical) | Typically 2–5% in cosmetic formulations | Topical (creams, serums, eye patches) | Extended Argireline with two additional amino acids. Claimed improved potency vs. Argireline. Minimal peer-reviewed efficacy data |
| Leuphasyl (Hexapeptide-11) | Synthetic hexapeptide (Palmitoyl-Pro-Asn-Thr-Asn-Leu-Ala, matrix metalloproteinase inhibitor proposed) | MMP inhibition (skin-matrix degradation prevention); collagen preservation | ~2–3 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Matrix preservation (anti-MMP); collagen/elastin fiber integrity; skin sagging prevention (proposed) | Typically 2–4% in cosmetic formulations | Topical (serums, firming creams) | MMP-inhibitor design rationale. Alternative to collagen-upregulating peptides. Limited cosmetic industry data |
| Palmitoyl Tripeptide-1 (Pal-GHK) | Synthetic tripeptide conjugated to palmitic acid (Pal-Gly-His-Lys, copper-chelating glycine-histidine-lysine) | Copper chelation (collagen synthesis via Lox upregulation); wound healing reactivation | ~1–2 hours (topical) | Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Dermal collagen cross-linking; elastin remodeling; scar remodeling (proposed) | Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) | Topical (anti-aging serums, creams) | Core component of Matrixyl and Matrixyl 3000. Copper-dependent mechanism. Palmitoyl modification enhances skin penetration |
| Palmitoyl Tetrapeptide-7 (Pal-GHKGQ) | Synthetic tetrapeptide conjugated to palmitic acid (Pal-Gly-His-Lys-Gly-Gln, extended GHK variant with elastin-targeting residues) | Elastin upregulation; integrin signaling activation (proposed); elastin-specific pathway | ~1–3 hours (topical) | Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Elastin remodeling (distinct from collagen pathway); skin elasticity and bounce; fine-line reduction (proposed) | Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) | Topical (anti-aging serums, firming creams) | Extended GHK variant targeting elastin specifically. Synergistic with Palmitoyl Tripeptide-1 in Matrixyl 3000 |
| Syn-Ake (Dipeptide Diethylaminobutyroyl Benzylamide Diacetate, Snake Venom Mimetic Peptide) | Synthetic dipeptide-conjugate mimicking snake venom neurotoxins (synthetic neuro-blocking peptide) | Neuromuscular junction analog blockade (topical snake venom mimic); acetylcholine inhibition | ~2–4 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Expression line relaxation (periorbital wrinkles); dynamic wrinkle reduction (snake venom analog mechanism topical) | Typically 1–3% in cosmetic formulations | Topical (eye creams, serums, patches) | Snake venom analog mechanism. Branded as natural-origin alternative to botulinum toxin. Limited clinical efficacy studies |
| Acetyl Tetrapeptide-5 (SNAP-25 Mimic) | Synthetic tetrapeptide (Ac-Glu-Glu-Met-Gln, acetylated SNARE domain fragment) | SNAP-25 modulation (neuromuscular junction-like topical effect, proposed) | ~1–3 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Expression lines (wrinkle reduction, proposed Botox analog); muscle-relaxation topical effect | Typically 2–5% in cosmetic formulations | Topical (anti-wrinkle serums, creams) | Short SNAP-25 fragment. Purported Botox alternative via topical neuromuscular effects. Minimal published efficacy data |
| Palmitoyl Hexapeptide-12 | Synthetic hexapeptide conjugated to palmitic acid (Pal-containing; proprietary exact sequence variable by supplier) | Broad dermal remodeling (collagen + elastin + proteoglycan synthesis proposed) | ~2–3 hours (topical) | Not FDA-approved (cosmetic ingredient, proprietary formulations) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Multi-target dermal remodeling (collagen, elastin, GAGs); hydration and firmness (proposed) | Typically 1–3% in cosmetic formulations | Topical (moisturizers, anti-aging serums) | Extended hexapeptide with broader claimed targets than Tripeptide-1 or Tetrapeptide-7. Proprietary variations limit standardization |
| AHK-Cu (Copper Tripeptide: Ala-His-Lys + Cu²⁺) | Synthetic tripeptide-copper complex (alanine-histidine-lysine chelated to Cu²⁺, GHK-Cu analog) | Collagen synthesis (copper-dependent lysyl oxidase activation); similar mechanism to GHK-Cu topical | ~1–2 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Dermal collagen remodeling; anti-aging (collagen-dependent wrinkle reduction); scar appearance improvement | Typically 0.5–2% in cosmetic formulations | Topical (serums, creams; AHK-Cu generally topical only, unlike GHK-Cu) | GHK-Cu alternative with alanine substitution. More stable copper complex than GHK-Cu in some formulations. Cosmetic-grade copper peptide |
| Tripeptide-29 (Proprietary Sequence, Collagen-Targeting Peptide) | Synthetic tripeptide (exact sequence proprietary; collagen I/III targeting proposed) | Collagen-specific upregulation (proprietary mechanism); dermal matrix support | ~1–2 hours (topical) | Not FDA-approved (cosmetic ingredient) | Not WADA-listed (topical cosmetic peptide) | Tier 4 — Preclinical Only | Collagen I and III upregulation; skin resilience and firmness (proposed); anti-sagging | Typically 1–2% in cosmetic formulations | Topical (anti-aging creams, serums) | Proprietary peptide composition (exact sequence not published). Limited third-party efficacy studies |
Summary and Key Takeaways
Palmitoyl hexapeptide-12 has the weakest evidence position of any compound in Cluster G. The proposed mechanism — NMJ acetylcholine inhibition — is the same functional category as argireline, leuphasyl, and Syn-Ake, but the specific molecular target is not characterized in available public literature. No published peer-reviewed clinical trials exist. No PubMed-indexed mechanistic studies exist for the cosmetic NMJ-inhibiting activity of this compound. The evidence position is supplier product sheets. This is not adequate evidence for clinical efficacy claims, and anyone choosing whether to include this compound in a formulation or self-experimentation protocol should understand that distinction clearly.
- Palmitoyl hexapeptide-12 (Pal-VGVAPG) is a palmitoylated elastin-derived hexapeptide proposed to reduce facial muscle contraction by inhibiting acetylcholine release at the NMJ. The specific molecular target is not characterized in available public literature.
- Evidence tier: preclinical — and at the floor of that tier. No published clinical trials. No published mechanistic studies for NMJ activity. Supplier product sheets only. This is the weakest evidence position in Cluster G and among the weakest in the Peptidings compound library.
- Molecular weight ~1,025 Da — one of the heaviest in Cluster G, comparable to Snap-8. Substantial passive penetration barrier. Palmitoyl delivery strategy is appropriate but the NMJ target depth remains a challenge regardless of delivery enhancement.
- The VGVAPG sequence does have independent published biology — but as an elastin-derived chemoattractant/EBP ligand, not as an NMJ inhibitor. Independent literature on the sequence does not validate the cosmetic NMJ claim.
- Topical use is low-risk based on palmitoylated peptide category safety profile. Microneedling has penetration rationale given the high MW. SC injection has no evidence and the palmitoyl delivery chemistry argues against systemic administration.
- Formulation decision: if the goal is comprehensive NMJ inhibition, argireline + leuphasyl + Syn-Ake covers three mechanistically independent and better-characterized pathways. Adding palmitoyl hexapeptide-12 adds a fourth NMJ claim with the weakest supporting evidence of the group and unknown molecular target — whether it adds clinical benefit is genuinely unknown.
- WADA: not prohibited. Bont-L Peptide® is a tradename associated with Infinitec Activos. Generic palmitoyl hexapeptide-12 from other suppliers is chemically equivalent.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Selected References and Key Studies
- Mecham RP, et al. Elastin is chemotactic for fibroblasts: characterization of an elastin-derived pentapeptide. J Cell Biol. 1989;109(1):349–56. PMID 2745550 — VGVAPG elastin-derived peptide biology; independent academic context for the sequence
- Duca L, et al. Elastin as a matrikine. Crit Rev Oncol Hematol. 2004;49(3):235–44. PMID 15036264 — elastin-derived peptide signaling and EBP receptor biology
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–45. PMID 19624730
- Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303–10. PMID 18494926 — NMJ mechanism context; the evidence standard palmitoyl hexapeptide-12 does not meet
Further Reading and References
- Skin & Cosmetic Research Cluster — Peptidings.com — all 12 compounds with evidence tiers and delivery route data
- Argireline: Research Overview — Peptidings.com — the NMJ-targeting peptide with the best published evidence; the standard palmitoyl hexapeptide-12 does not approach
- Leuphasyl: Research Overview — Peptidings.com — enkephalin pathway NMJ inhibitor; mechanistically characterized and complementary to argireline
- Syn-Ake: Research Overview — Peptidings.com — postsynaptic nAChR antagonist; the third mechanistically independent NMJ inhibitor with better evidence than palmitoyl hexapeptide-12
- Snap-8: Research Overview — Peptidings.com — extended SNARE inhibitor; also preclinical, but with more described manufacturer data than palmitoyl hexapeptide-12
- More Is Not Always More — Peptidings.com — NMJ peptide stacking logic; when adding more compounds adds value and when it does not
- INCIDecoder: Palmitoyl Hexapeptide-12 — ingredient database with product occurrence data
- Evidence Levels Explained — Peptidings.com — how to interpret the evidence hierarchy used throughout this site
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any cosmetic product, formulation, or delivery method.
Palmitoyl hexapeptide-12 is a cosmetic ingredient, not an FDA-approved drug. It has not been evaluated by the FDA for safety or efficacy. Bont-L Peptide® is a tradename associated with Infinitec Activos; generic palmitoyl hexapeptide-12 from other suppliers is chemically equivalent at equivalent concentration.
The absence of published clinical evidence for this compound is noted explicitly and is a central finding of this review. Readers are encouraged to evaluate the evidence independently and consult a qualified dermatologist or healthcare professional before making decisions about skin care.
← Previous